THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Applera board of directors approves spin-off of Celera Group

Email|Print|Single Page| Text size – +
May 9, 2008

NORWALK, Conn.—Pharmaceutical company Applera Corp. said Friday its board had approved the spin-off of its Celera Group business into a separate, publicly traded entity. The separation is expected to close July 1.

The separation would be achieved through a one-for-one redemption of Applera Corp.-Celera Group tracking stock in exchange for common stock of Celera Corp. A tracking stock is issued by the parent company to invest in one division without taking on risks and benefits of other businesses. Celera is Applera's diagnostics and medical testing business. Applera also has a genetic analyst business called Applied Biosystems.

Kathy Ordonez, president of the Celera Group, will serve as the company's chief executive.

Shares of Applera were down 7 cents to $33.69 in midday trading, while Celera tracking shares rose 14 cents to $12.72.

© Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

more stories like this

  • Email
  • Email
  • Print
  • Print
  • Single page
  • Single page
  • Reprints
  • Reprints
  • Share
  • Share
  • Comment
  • Comment
 
  • Share on DiggShare on Digg
  • Tag with Del.icio.us Save this article
  • powered by Del.icio.us
Your Name Your e-mail address (for return address purposes) E-mail address of recipients (separate multiple addresses with commas) Name and both e-mail fields are required.
Message (optional)
Disclaimer: Boston.com does not share this information or keep it permanently, as it is for the sole purpose of sending this one time e-mail.